Arkolith/Insider Trading/CTNM/Form 4

Stengone Carmine N.

CEO and President, DirectorContineum Therapeutics, Inc. (CTNM) · full profile →Form 4 · filed Feb 26, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$114K
Net Open-Market Flow
-$114K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 25, 2026Option exercise(M)3K$1.26$3K18K
Feb 25, 2026Sell(S)3K$16.02$43K15K
Feb 24, 2026Option exercise(M)4K$1.26$6K19K
Feb 24, 2026Sell(S)4K$16.02$70K15K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 25, 2026Option exercise(M)3K—$0121K
Feb 24, 2026Option exercise(M)4K—$0124K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-26-005892) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML